• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

ADALIMUMAB Drug Record

  • Summary
  • Interactions
  • Claims
  • ADALIMUMAB chembl:CHEMBL1201580 ApprovedImmunotherapy

    Alternate Names:

    MSB-11022
    CT-P17
    D2E7
    MSB11022
    ZRC3197
    BI695501
    FKB-327
    FKB327
    LU200134
    GP2017
    AVT-02
    HLX03
    ADALIMUMAB
    ADALIMUMAB (GENETICAL RECOMBINATION)
    ADALIMUMAB BETA
    HLX-03
    LU-200134
    M923
    HUMIRA
    ZRC-3197
    HUMIRA®
    IG GAMMA-1 CHAIN C REGION
    drugbank:00051
    chemidplus:331731-18-1
    rxcui:327361
    chembl:CHEMBL1201580

    Drug Info:

    Year of Approval 2002
    Drug Class antirheumatic agents
    FDA Approval approved
    Drug Class monoclonal antibody
    Drug Indications antiinflammatory agent,DMARD
    (2 More Sources)

    Publications:

    Deželak M et al., 2016, A Prospective Pharmacogenomic Study of Crohn's Disease Patients during Routine Therapy with Anti-TNF-α Drug Adalimumab: Contribution of ATG5, NFKB1, and CRP Genes to Pharmacodynamic Variability., OMICS
    Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine
    Song GG et al., 2015, Association between TNF-α (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-α blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis., Pharmacogenomics
    Tong Q et al., 2013, Association of TNF-α polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis., Pharmacogenomics
    Tong Q et al., 2012, TNF-α -857 and -1031 polymorphisms predict good therapeutic response to TNF-α blockers in Chinese Han patients with ankylosing spondylitis., Pharmacogenomics
    Lacruz-Guzmán D et al., 2013, Influence of polymorphisms and TNF and IL1β serum concentration on the infliximab response in Crohn's disease and ulcerative colitis., Eur J Clin Pharmacol
    Zeng Z et al., 2013, Association between tumor necrosis factor-α (TNF-α) promoter -308 G/A and response to TNF-α blockers in rheumatoid arthritis: a meta-analysis., Mod Rheumatol
    Daïen CI et al., 2012, TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis., Joint Bone Spine
    O'Rielly DD et al., 2009, TNF-alpha-308 G/A polymorphism and responsiveness to TNF-alpha blockade therapy in moderate to severe rheumatoid arthritis: a systematic review and meta-analysis., Pharmacogenomics J
    Maxwell JR et al., 2008, Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis., Hum Mol Genet
    Marotte H et al., 2008, Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor., Arthritis Rheum
    Guis S et al., 2007, Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis., Arthritis Rheum
    Cuchacovich M et al., 2006, Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis., Scand J Rheumatol
    Lee YH et al., 2006, Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis., Rheumatol Int
    Seitz M et al., 2007, The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients., Rheumatology (Oxford)
    Mugnier B et al., 2003, Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis., Arthritis Rheum
    Louis E et al., 2002, A positive response to infliximab in Crohn disease: association with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism., Scand J Gastroenterol
    Bang et al., 2004, Adalimumab: a review of its use in rheumatoid arthritis., BioDrugs
    Aguillón et al., 2003, [New immunological weapons for medicine in the 21st Century: biological therapy based on the use of the latest generation monoclonal antibodies]., Rev Med Chil
    Klinkhoff, 2004, Biological agents for rheumatoid arthritis: targeting both physical function and structural damage., Drugs
    Flendrie et al., 2003, Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis., Ann. Rheum. Dis.
    Chen et al., 2002, TTD: Therapeutic Target Database., Nucleic Acids Res.
    Lorenz, 2002, Technology evaluation: adalimumab, Abbott laboratories., Curr. Opin. Mol. Ther.
    Iwaszko M et al., 2015, Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy., Clin Exp Immunol
    Mendrinou E et al., 2017, FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFα inhibitors., Pharmacogenomics J
    Dávila-Fajardo CL et al., 2015, FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis., Pharmacogenomics
    Montes A et al., 2014, Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis., Pharmacogenet Genomics
    Julià M et al., 2013, The role of Fcγ receptor polymorphisms in the response to anti–tumor necrosis factor therapy in psoriasis A pharmacogenetic study., JAMA Dermatol
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Pappas DA et al., 2013, Association of rheumatoid arthritis risk alleles with response to anti-TNF biologics: results from the CORRONA registry and meta-analysis., Inflammation
    Cui J et al., 2010, Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy., Arthritis Rheum
    Repnik K et al., 2016, Transferrin Level Before Treatment and Genetic Polymorphism in HFE Gene as Predictive Markers for Response to Adalimumab in Crohn's Disease Patients., Biochem Genet
    Ovejero-Benito MC et al., 2018, Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis., Pharmacogenomics
    Morales-Lara MJ et al., 2012, Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis., Joint Bone Spine
    Dávila-Fajardo CL et al., 2014, Confirmation of -174G/C interleukin-6 gene promoter polymorphism as a genetic marker predicting antitumor necrosis factor treatment outcome., Pharmacogenet Genomics
    Koder S et al., 2015, Genetic polymorphism in ATG16L1 gene influences the response to adalimumab in Crohn's disease patients., Pharmacogenomics
  • ADALIMUMAB   ATG16L1

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    25712183


    Sources:
    PharmGKB

  • ADALIMUMAB   HFE

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27115882


    Sources:
    PharmGKB

  • ADALIMUMAB   ATG5

    Interaction Score: 7.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27096233


    Sources:
    PharmGKB

  • ADALIMUMAB   IVL

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29192552


    Sources:
    PharmGKB

  • ADALIMUMAB   TF

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27115882


    Sources:
    PharmGKB

  • ADALIMUMAB   FCGR2A

    Interaction Score: 3.64

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27044681 25823785 24667440 24048425 17016423 17139284


    Sources:
    PharmGKB

  • ADALIMUMAB   TRAF1

    Interaction Score: 2.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23007924


    Sources:
    PharmGKB

  • ADALIMUMAB   CRP

    Interaction Score: 2.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    27096233


    Sources:
    PharmGKB

  • ADALIMUMAB   TNFRSF1A

    Interaction Score: 1.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22480748


    Sources:
    PharmGKB

  • ADALIMUMAB   ATP5F1E

    Interaction Score: 1.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26307125


    Sources:
    PharmGKB

  • ADALIMUMAB   KLRD1

    Interaction Score: 1.82

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26453102


    Sources:
    PharmGKB

  • ADALIMUMAB   TNF

    Interaction Score: 1.39

    Interaction Types & Directionality:
    antibody (inhibitory)
    inhibitor (inhibitory)

    Interaction Info:
    Mechanism of Interaction TNF-alpha inhibitor
    Direct Interaction yes
    Trial Name Humira

    PMIDs:
    26244882 24192118 23057546 22960943 22760475 22129793 19365401 18713756 18438841 18050183 17343250 16909270 16720636 12847678 12190096 15046527 15022409 15200343 14532145 11752352 12044041


    Sources:
    TdgClinicalTrial ChemblInteractions TEND PharmGKB TTD

  • ADALIMUMAB   PTPRC

    Interaction Score: 0.91

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    23007924 20309874


    Sources:
    PharmGKB

  • ADALIMUMAB   HLA-E

    Interaction Score: 0.91

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • ADALIMUMAB   FCGR3A

    Interaction Score: 0.76

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    17016423 17139284 27044681 24048425


    Sources:
    PharmGKB

  • ADALIMUMAB   IL6

    Interaction Score: 0.29

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    24253594


    Sources:
    PharmGKB

  • ADALIMUMAB   HLA-DRB1

    Interaction Score: 0.12

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • TEND: ADALIMUMAB

    • Version: 01-August-2011

    Alternate Names:
    ADALIMUMAB Primary Drug Name

    Drug Info:
    Drug Class antirheumatic agents
    Year of Approval 2002

    Publications:

  • TdgClinicalTrial: ADALIMUMAB

    • Version: January-2014

    Alternate Names:

    Drug Info:
    Drug Indications antiinflammatory agent,DMARD
    Drug Class monoclonal antibody
    FDA Approval approved

    Publications:

  • PharmGKB: adalimumab

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Iwaszko M et al., 2016, Influence of CD94 and NKG2A variants on susceptibility to rheumatoid arthritis and efficacy of anti-TNF treatment., Joint Bone Spine
    Iwaszko M et al., 2015, Polymorphisms within the human leucocyte antigen-E gene and their associations with susceptibility to rheumatoid arthritis as well as clinical outcome of anti-tumour necrosis factor therapy., Clin Exp Immunol
    Ovejero-Benito MC et al., 2018, Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis., Pharmacogenomics

  • TTD: Adalimumab

    • Version: 2020.06.01

    Alternate Names:
    D0K5KS TTD Drug ID

    Drug Info:

    Publications:

  • ChemblInteractions: CHEMBL1201580

    • Version: chembl_23

    Alternate Names:

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL1201580

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21